Leukemia, Myeloid, Acute

<section class="Section" data-sectioncode="34089-3"><a name="ID_82298122-307f-49a3-80a2-a234f7a5c640"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION  </h1><p class="First">Gilteritinib is a kinase inhibitor. The chemical name is 2-Pyrazinecarboxamide, 6-ethyl-3-[[3-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl] phenyl] amino]-5-[(tetrahydro-2<span class="Italics">H</span>-pyran-4-yl) amino]-, (2<span class="Italics">E</span>)-2-butenedioate (2:1). The molecular weight is 1221.50 and the molecular formula is (C<span class="Sub">29</span>H<span class="Sub">44</span>N<span class="Sub">8</span>O<span class="Sub">3</span>)<span class="Sub">2</span>·C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span>. The structural formula is:</p><div class="Figure"><a name="id-432291317"></a><img alt="Structural Formula of Gilteritinib" src="image-01.jpg"/></div><p>Gilteritinib fumarate is a light yellow to yellow powder or crystals that is sparingly soluble in water and very slightly soluble in anhydrous ethanol.</p><p>XOSPATA (gilteritinib) is provided as a tablet for oral administration. Each tablet contains 40 mg of gilteritinib active ingredient as free base (corresponding to 44.2 mg gilteritinib fumarate). The inactive ingredients are ferric oxide, hydroxypropyl cellulose, hypromellose, low-substituted hydroxypropyl cellulose, mannitol, magnesium stearate, polyethylene glycol, talc, and titanium dioxide.</p></section>

Xospata

gilteritinib

gilteritinib 40 MG Oral Tablet

gilteritinib 40 MG Oral Tablet [Xospata]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Reimbursement Information

Pharmacy List 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Xospata Support Solutions Patient Enrollment Form

Other HCP Resources - Forms 

Quick Start Program - One-time 7-day Supply

Enroll in Patient Savings Program 

 Astellas Patient Assistance Program

Xospata Support Solutions

About Xospata 

Side Effects 

Taking Xospata 

Patient Stories 

Patient Resources

FAQs: AML w/FLT3 Mutation 

Instructions For Use: AML w/FLT3 Mutation 

Caregiver Resources 

Managing Treatment At Home

Patient Brochure 

Xospata Support Solutions Brochure

Dosing Tracker

For Caregiver: Questions To Ask The Doctor